ECT Indications and Contraindications

Primary Indications for ECT

• The American Academy of Child and Adolescent Psychiatry recommends ECT for severe, persistent major depression (with or without psychotic features) 1
• The American Academy of Child and Adolescent Psychiatry suggests ECT for mania (with or without psychotic features) 1
• The American Academy of Child and Adolescent Psychiatry indicates ECT for schizoaffective disorder 1
• The American Academy of Child and Adolescent Psychiatry recommends ECT for schizophrenia (particularly with prominent affective symptoms) 2
• The American Academy of Child and Adolescent Psychiatry advises ECT for catatonia (regardless of underlying diagnosis) 1
• The American Academy of Child and Adolescent Psychiatry recommends ECT for neuroleptic malignant syndrome 2

When Anxiety Might Be Addressed by ECT

• The American Academy of Child and Adolescent Psychiatry notes that ECT may indirectly benefit anxiety symptoms when they occur as part of a primary mood disorder or psychotic condition that meets ECT criteria 3
• The American Academy of Child and Adolescent Psychiatry states that comorbid anxiety disorders with severe mood disorders should not contraindicate ECT 3

Required Criteria Before ECT Consideration

• The American Academy of Child and Adolescent Psychiatry requires an appropriate diagnosis, which includes one of the primary indications listed above (not anxiety disorder alone), before considering ECT 3
• The American Academy of Child and Adolescent Psychiatry mandates severe, life-threatening symptoms, including refusal to eat/drink, severe suicidality, uncontrollable mania, or florid psychosis, before ECT consideration 4
• The American Academy of Child and Adolescent Psychiatry necessitates treatment resistance, defined as failure of at least two adequate medication trials, unless the patient cannot tolerate medications or waiting endangers life 5

Electroconvulsive Therapy Indications and Management

Patient Selection and Indications

• The American Academy of Child and Adolescent Psychiatry suggests that ECT can be used to treat schizophrenia, particularly with prominent affective symptoms or during acute exacerbations of positive symptoms, in patients who have not responded to other treatments 6
• Patients with personality disorders, including those with severe symptoms, can benefit from ECT, as it does not contraindicate its use, according to the American Academy of Child and Adolescent Psychiatry 7
• The American Academy of Child and Adolescent Psychiatry also states that mental retardation is not a contraindication for ECT 8
• Seizure disorders do not preclude ECT and may even improve with treatment, as noted by the American Academy of Child and Adolescent Psychiatry 7, 8

Post-ECT Management and Side Effects

• The American Academy of Child and Adolescent Psychiatry recommends that after ECT, patients should receive continuation treatment, such as pharmacotherapy tailored to the presenting disorder, to prevent relapse 9
• Common side effects of ECT include cognitive effects, such as memory impairment, which may persist for approximately 2 months post-treatment, as well as acute side effects like headache, nausea, and vomiting, which typically resolve within the day of treatment 9
• Prolonged seizures can occur in 0-10% of treatments and should be treated promptly with additional methohexital, diazepam, or lorazepam, according to the American Academy of Child and Adolescent Psychiatry 9

ECT for Treatment-Resistant Depression

Primary Indications for ECT in Depression

• The American Academy of Child and Adolescent Psychiatry recommends considering ECT after failure of two adequate antidepressant trials, though it may be used as first-line therapy when symptoms are life-threatening, particularly in patients with life-threatening symptoms, including refusal to eat or drink, severe suicidality, or profound psychomotor retardation 10
• ECT is indicated for patients who have failed two or more adequate antidepressant trials, defined as 8-10 weeks at therapeutic doses with confirmed adherence, according to the American Academy of Child and Adolescent Psychiatry and supported by evidence from Depression and Anxiety 10, 11

Treatment-Resistant Depression Criteria

• The American Academy of Child and Adolescent Psychiatry suggests confirming true treatment resistance by ensuring adequate trial duration of at least 8-10 weeks per antidepressant at therapeutic doses, and verifying medication adherence through pill counts, serum levels, or supervised administration 10
• Two distinct medication classes should have failed for unipolar depression, and symptoms must be severe, persistent, and significantly disabling, as recommended by the American Academy of Child and Adolescent Psychiatry 10

Contraindications

• The American Academy of Child and Adolescent Psychiatry states that there are no absolute contraindications to ECT, and conditions previously considered contraindications, such as cerebral tumors, recent myocardial infarction, and active chest infections, are now only relative concerns 12

ECT Augmentation in Treatment-Resistant Depression

Patient Selection

• Patients who have failed multiple medication trials, including those who have failed augmentation strategies, structured psychotherapy, and transcranial magnetic stimulation (TMS), may be considered for ECT 13
• The American Psychiatric Association suggests that ECT can be considered for patients with treatment-resistant depression, including those with multiple-drug resistance, and those who have failed other treatment modalities 13

Treatment Considerations

• The National Institute of Mental Health recommends that patients who have failed deep brain stimulation (DBS) or vagus nerve stimulation (VNS) should be considered for ECT in clinical practice, although they may be excluded from clinical studies 13
• The strength of evidence for ECT effectiveness in treatment-resistant depression is high, with response rates of 65.8% and remission rates of 53.3% in patients who have failed an average of 5.4 different pharmacological treatments 13

ECT as Augmentation for Antidepressant Medication in Treatment-Resistant Depression

When to Consider ECT Augmentation

• The American Academy of Child and Adolescent Psychiatry recommends considering ECT after failure of two adequate antidepressant trials, with response rates of 65-70% and remission rates of 50-60% even in severely treatment-resistant patients 14
• ECT can be used earlier when symptoms are life-threatening, such as refusal to eat/drink, severe suicidality, uncontrollable mania, or florid psychosis, with the goal of achieving response rates of 65-70% and remission rates of 50-60% 14

ECT Effectiveness in Treatment-Resistant Populations

• ECT demonstrates superior efficacy compared to pharmacotherapy alone, with response rates of 65-80% substantially exceeding those of medication monotherapy or augmentation strategies 15

Important Caveats

• The American Academy of Child and Adolescent Psychiatry suggests that ECT may be considered before completing two medication trials when the patient cannot tolerate medications at therapeutic doses, is too incapacitated to take medication, or is at risk of endangering their life 14
• The American Academy of Child and Adolescent Psychiatry recommends that ECT can be considered earlier in patients with severe, persistent major depression, mania, schizoaffective disorder, or schizophrenia with prominent affective symptoms, with a diagnosis established through thorough evaluation 14